Cryopreservation of biological materials law

Introduction

Cryopreservation of biological materials refers to the scientific process of preserving living cells, tissues, embryos, reproductive materials, microorganisms, stem cell lines, and other biological specimens at extremely low temperatures to maintain their biological characteristics for future use. This technology plays an important role in biotechnology, reproductive medicine, pharmaceutical research, genetic conservation, organ transplantation, and biomedical innovation.

Cryopreservation generally involves controlled cooling and the use of cryoprotective agents to minimise cellular damage caused by ice formation. Biological materials may be stored in specialised facilities using liquid nitrogen or other controlled-temperature systems.

The legal regulation of cryopreservation is particularly important because preserved biological materials may contain human genetic information, reproductive potential, commercially valuable biological resources, and sensitive medical information. Their collection, storage, transportation, ownership, utilisation, and destruction raise complex legal questions concerning informed consent, privacy, human dignity, property rights, biosafety, and institutional accountability.

For example, embryos preserved during assisted reproductive procedures may remain in storage for several years, creating legal questions concerning continued consent, reproductive autonomy, ownership disputes, and their eventual disposal. Similarly, cryopreserved stem cell lines may be used for scientific research, pharmaceutical development, or future therapeutic applications.

International legal framework governing cryopreservation

There is no single comprehensive international treaty exclusively regulating cryopreservation of all biological materials. Instead, different international instruments establish relevant principles depending on the biological material and its intended use.

The UNESCO Universal Declaration on Bioethics and Human Rights, 2005, establishes principles concerning human dignity, informed consent, privacy, and the ethical utilisation of biological materials.

The Convention on Human Rights and Biomedicine (Oviedo Convention), 1997, provides important protections concerning human dignity, biomedical research, and the human body. Its provisions are particularly relevant to embryo-related research and the use of human biological materials in participating states.

The World Health Organization (WHO) provides technical guidance concerning the quality, safety, and handling of human cells, tissues, and other biological materials.

Other relevant frameworks include:

International Health Regulations, 2005: Relevant to certain public health risks associated with international biological material movements.

Convention on Biological Diversity, 1992: Relevant to covered biological resources and biodiversity conservation.

Nagoya Protocol, 2010: Establishes access and benefit-sharing obligations concerning genetic resources within its scope.

ISSCR Guidelines, 2021: Provide ethical standards for stem cell research, storage, sharing, and clinical translation.

UNESCO Universal Declaration on the Human Genome and Human Rights, 1997: Addresses human genetic dignity, privacy, and responsible genetic research.

These instruments establish important ethical and regulatory principles, although their applicability depends on the nature and origin of the preserved material.

Informed consent and ownership of biological materials

Informed consent is one of the most important legal requirements governing the cryopreservation of human biological materials.

Individuals donating sperm, eggs, embryos, stem cells, blood, or tissue samples must receive adequate information concerning the purpose of preservation, storage duration, future utilisation, possible research applications, and conditions for disposal.

Consent should also clarify whether the biological material may be used for scientific research, commercial development, reproductive treatment, or transfer to another institution.

A major legal difficulty arises when individuals withdraw consent after biological materials have already been preserved. This is particularly significant in assisted reproductive technology, where disagreement between reproductive partners may affect the continued storage or utilisation of embryos.

Legal ownership of cryopreserved materials is not always equivalent to ordinary property ownership. Courts may need to consider personal autonomy, reproductive rights, contractual obligations, and the special ethical status of human biological materials.

Storage facilities and institutional responsibilities

Cryopreservation facilities must maintain appropriate environmental conditions to protect the quality and viability of stored biological materials.

Storage failures may result from equipment malfunction, temperature fluctuations, power interruptions, inadequate monitoring, human error, or insufficient emergency planning.

Institutions operating cryopreservation facilities therefore have important legal and professional responsibilities.

These include:

Maintaining validated cryogenic storage systems.

Monitoring storage temperatures continuously.

Maintaining backup equipment and emergency arrangements.

Ensuring proper identification and traceability of samples.

Preventing contamination and unauthorised access.

Maintaining accurate storage and inventory records.

Establishing procedures for equipment failure and sample transfer.

Protecting confidential donor and patient information.

Facilities may also face contractual or professional liability where negligent storage causes the loss or deterioration of biological materials.

Cryopreservation in reproductive medicine

Cryopreservation is widely used in assisted reproductive technology (ART), particularly for preserving embryos, sperm, and oocytes.

Embryo cryopreservation allows individuals to preserve reproductive options for future treatment. However, long-term storage creates complex legal issues concerning consent, reproductive autonomy, disputes between former partners, and the disposal of unused embryos.

In India, the Assisted Reproductive Technology (Regulation) Act, 2021, and the Assisted Reproductive Technology (Regulation) Rules, 2022, provide the principal statutory framework governing ART services and related activities.

The legislation regulates ART clinics and banks, registration requirements, donor-related matters, consent, and the handling of reproductive materials.

The Surrogacy (Regulation) Act, 2021, may also become relevant in circumstances involving reproductive arrangements covered by that legislation.

These laws aim to ensure that reproductive technologies operate within an appropriate framework of medical standards, informed consent, and ethical responsibility.

Cryopreservation of stem cells and biological research materials

Cryopreservation is essential for maintaining stem cell lines, cell cultures, microbial specimens, and other biological research materials.

Stem cell banks preserve biological materials for future research, disease modelling, drug development, and potentially therapeutic applications.

In India, the ICMR-DBT National Guidelines for Stem Cell Research, 2017, establish ethical and scientific requirements concerning stem cell derivation, banking, storage, and research utilisation.

Research institutions must ensure that biological materials are stored according to validated procedures and used only for authorised purposes.

Where cryopreserved materials contain human-derived genetic information, applicable privacy and confidentiality obligations must also be considered.

Data protection and genetic privacy

Cryopreserved biological materials may contain highly sensitive genetic and medical information. Even when the physical specimen is securely stored, associated digital records may create privacy risks.

For example, stored stem cell samples may be linked to donor identity, medical history, genetic sequencing information, or reproductive records.

In India, the Digital Personal Data Protection Act, 2023, may apply to associated digital personal data within its scope.

Under the European Union's GDPR, genetic and health information may receive special-category protection under Article 9, where the regulation applies.

Cryopreservation facilities should therefore establish appropriate access controls, data minimisation procedures, encryption, confidentiality agreements, and policies governing the sharing of genetic information.

Indian legal and regulatory framework

The principal Indian laws and regulatory frameworks relevant to cryopreservation include:

1. Assisted Reproductive Technology (Regulation) Act, 2021

The Act regulates ART clinics and banks and establishes requirements concerning reproductive materials, consent, donor-related procedures, and institutional registration.

It is particularly relevant to the preservation and handling of sperm, oocytes, and embryos.

2. Assisted Reproductive Technology (Regulation) Rules, 2022

These Rules provide operational and regulatory requirements for ART establishments, including the functioning of ART clinics and banks.

3. National Guidelines for Stem Cell Research, 2017

Issued jointly by ICMR and DBT, these guidelines establish ethical and scientific requirements for stem cell research, banking, storage, and clinical applications.

4. Drugs and Cosmetics Act, 1940, and applicable rules

These provisions may become relevant where preserved biological materials are processed or used in regulated drug and biological product manufacturing.

5. Digital Personal Data Protection Act, 2023

The Act provides a framework for protecting associated digital personal information, including identifiable medical and genetic records within its scope.

6. Environment (Protection) Act, 1986

The Act and relevant subordinate rules may apply where cryopreservation facilities handle hazardous microorganisms, genetically engineered materials, or regulated biological waste.

Case laws and judicial decisions

Although there is limited direct judicial precedent specifically addressing cryopreservation facilities, several landmark decisions establish important principles concerning reproductive autonomy, embryo preservation, biological material ownership, informed consent, and medical negligence.

1. Evans v. United Kingdom (2007), Application No. 6339/05

The European Court of Human Rights examined a dispute involving embryos created through assisted reproduction and preserved through cryopreservation.

Following the withdrawal of consent by one reproductive partner, the applicant sought permission to continue using the stored embryos.

The court examined reproductive autonomy, consent requirements, and the competing rights of the individuals involved.

Legal significance: The judgment establishes the importance of continuing consent in embryo-related procedures. It demonstrates that cryopreserved embryos create legal questions that extend beyond their physical storage and involve reproductive autonomy and individual rights.

2. Davis v. Davis (1992), 842 S.W.2d 588

The Tennessee Supreme Court considered a dispute between former spouses concerning the future use of cryopreserved embryos.

The court examined whether the embryos should be treated as ordinary property and considered the competing reproductive interests of the parties.

It concluded that pre-embryos occupy an interim category that deserves special respect because of their potential for human development.

Legal significance: This judgment is important because it demonstrates that disputes involving cryopreserved embryos require consideration of reproductive autonomy, contractual intentions, and ethical interests rather than ordinary property principles alone.

3. York v. Jones (1989), 717 F. Supp. 421

A United States federal court considered a dispute concerning the attempted transfer of a cryopreserved human embryo between fertility institutions.

The dispute involved contractual arrangements and the rights of the individuals seeking the transfer of their preserved embryo.

Legal significance: The judgment illustrates the importance of clearly drafted storage agreements, transfer rights, and institutional responsibilities when biological materials are preserved by third-party facilities.

4. J. v. M. (2012), EWCA Civ 1637

The English Court of Appeal considered a dispute involving embryos preserved through assisted reproductive technology and issues concerning consent and their future use.

The case illustrates the importance of applying statutory consent requirements to the storage and use of reproductive materials.

Legal significance: The decision reinforces the principle that reproductive material storage and utilisation must comply with applicable consent requirements and cannot be determined solely by contractual convenience.

5. Moore v. Regents of the University of California (1990), 51 Cal. 3d 120

The California Supreme Court examined a dispute involving biological materials removed from a patient and subsequently used for commercial scientific research.

The court rejected the conversion claim concerning the excised cells but recognised the importance of informed consent and disclosure of researchers' financial interests.

Legal significance: The decision is relevant to cryopreserved biological materials because preserved cells and tissues may acquire significant scientific and commercial value. It highlights the importance of transparent donor consent and disclosure of intended research uses.

6. Yearworth v. North Bristol NHS Trust (2009), EWCA Civ 37

The English Court of Appeal considered whether men whose sperm had been stored by a hospital could bring claims for the loss of their cryopreserved sperm following negligent storage.

The court recognised that the claimants could establish proprietary rights in the stored sperm for the purposes of their legal claims.

Legal significance: This is particularly important for cryopreservation law because it directly addresses the legal consequences of negligent storage of human reproductive material. It demonstrates that storage institutions may face legal liability when biological materials are lost through inadequate care.

Liability and regulatory challenges

Cryopreservation facilities may face legal liability when biological materials are lost, contaminated, damaged, or used without proper authorisation.

The nature of liability depends on the circumstances, applicable legislation, contractual obligations, and the relationship between the institution and the donor or patient.

Major legal challenges include:

Disputes concerning ownership and control of preserved materials.

Withdrawal or modification of donor consent.

Negligent storage and equipment failure.

Unauthorised research or commercial utilisation.

Improper disposal of biological specimens.

Privacy breaches involving genetic information.

Disputes concerning international transportation.

Lack of uniform regulations for different biological materials.

Institutions should adopt comprehensive storage agreements, emergency management procedures, consent documentation, insurance arrangements, and independent compliance audits.

Conclusion

Cryopreservation of biological materials is an essential technology in modern biotechnology, reproductive medicine, regenerative medicine, pharmaceutical research, and genetic conservation. However, the long-term preservation of biological materials creates significant legal responsibilities concerning informed consent, reproductive autonomy, storage safety, ownership, privacy, and institutional accountability.

In India, the Assisted Reproductive Technology (Regulation) Act, 2021, the Assisted Reproductive Technology (Regulation) Rules, 2022, and the ICMR-DBT National Guidelines for Stem Cell Research, 2017, provide important regulatory foundations.

Judicial decisions such as Evans v. United Kingdom, Davis v. Davis, York v. Jones, Moore v. Regents, and Yearworth v. North Bristol NHS Trust establish significant principles concerning embryo preservation, reproductive autonomy, biological material rights, informed consent, and negligent storage.

An effective cryopreservation governance framework must combine scientific safety standards with enforceable consent procedures, reliable storage systems, transparent contractual arrangements, and appropriate privacy protections. Such regulation is essential to protect donors, patients, research institutions, and the scientific integrity of preserved biological materials.